Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：10

作者：

Liu, Yi-Fu ^{[1
]}

Fu, Sheng-Qiang ^{[1
]}

Yan, Yu-Chang ^{[1
]}

Gong, Bin-Bin ^{[1
]}

Xie, Wen-Jie ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Sun, Ting ^{[1
]}

Ma, Ming ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;

D O I：

10.2147/DDDT.S291369

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.

引用

页码：639 / 649

页数：11

共 50 条

[21] Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
Kawahara, Takashi
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (10) : 837 - 838
[22] Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
Choi, Seungtaek
Lee, Andrew K.
DRUG HEALTHCARE AND PATIENT SAFETY, 2011, 3 : 107 - 119
[23] Gonadotropin-releasing Hormone Receptor Expression in Endometrial Cancer
Jeon, Yong-Tark
Kim, Yong-Beom
Park, So Yeon
Kim, Jae Weon
Park, Noh-Hyun
Kang, Soon-Beom
Song, Yong-Sang
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2009, 28 (01) : 19 - 22
[24] Mathematical Model for Gonadotropin Secretion under the Effect of Gonadotropin-Releasing Hormone and Gonadotropin-Releasing Hormone Receptor
Viroj Wiwanitkit
Sexuality and Disability, 2007, 25 : 41 - 43
[25] Mathematical model for gonadotropin secretion under the effect of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor
Wiwanitkit, Viroj
SEXUALITY AND DISABILITY, 2007, 25 (01) : 41 - 43
[26] Degarelix: A Gonadotropin-Releasing Hormone Antagonist for the Management of Prostate Cancer
Steinberg, Michael
CLINICAL THERAPEUTICS, 2009, 31 : 2312 - 2331
[27] Gonadotropin-releasing hormone agonist failure in a man with prostate cancer
Smith, MR
McGovern, FJ
JOURNAL OF UROLOGY, 2001, 166 (01): : 211 - 211
[28] Gonadotropin-Releasing Hormone Antagonists-A New Hope in Endometriosis Treatment?
Rzewuska, Anna Maria
Zybowska, Monika
Sajkiewicz, Ilona
Spiechowicz, Izabela
Zak, Klaudia
Abramiuk, Monika
Kulak, Krzysztof
Tarkowski, Rafal
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
[29] Relugolix: A Novel Gonadotropin-Releasing Hormone Antagonist for Prostate Cancer
Babu, Merin
Pavithran, Keechilat
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2021, 12 (01) : 26 - 28
[30] Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs
Huerta-Reyes, Maira
Maya-Nunez, Guadalupe
Allan Perez-Solis, Marco
Lopez-Munoz, Eunice
Guillen, Nancy
Olivo-Marin, Jean-Christophe
Aguilar-Rojas, Arturo
FRONTIERS IN ONCOLOGY, 2019, 9

← 1 2 3 4 5 →